Huntington’s Disease – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of HD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of HD for each country, as well as annualized case counts projected to the national population.

All patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and the other countries covered in this report. In addition to forecasting the incident patient population, we estimate the number of drug-treatment opportunities in the mature markets.

Clarivate Epidemiology’s HD forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with HD per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with HD per year?
  • How will improvements in survival change the number of people living with a diagnosis of HD?
  • How will the declining risk of recurrence change the number of people diagnosed with HD per year?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following HD patient populations:

  • Diagnosed manifest prevalent cases.
  • Diagnosed manifest incident cases.
  • Diagnosed manifest prevalent cases by drug treatment scheme.
  • Diagnosed manifest prevalent cases by stage of disease.
  • Diagnosed prevalent cases.
  • Diagnosed premanifest prevalent cases.
  • Diagnosed prevalent cases at risk.
  • Diagnosed prevalent cases by risk category.

Note: Coverage may vary by country and region.